“A Repurposed Duo: Empagliflozin-Metformin Triggers a Metabolic Crisis in Cervical Cancer by Disrupting the Acyl-CoA/CoA Ratio via Dual Inhibition of PPAT and CPT1A” (2025) Journal of Cancer Research Updates, 14, pp. 247–265. doi:10.30683/1929-2279.2025.14.26.